# US 2021/0259957 A1 · Topical regional neuro-affective therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0259957 A1
- Document ID: US20210259957A1
- Status: Published application
- Kind: A1
- Application number: 17/314,274
- Filed: 2021-05-07
- Published: 2021-08-26
- Earliest claimed: 2008-06-30
- Assignees: Afgin Pharma, LLC
- Applicants: Afgin Pharma, LLC
- Inventors: Ronald Aung-Din
- Web page: https://patentgrep.com/patent/US20210259957A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/4458: only substituted in position 2, e.g. methylphenidate
- A61P 9/06: Antiarrhythmics
- A61P 15/10: for impotence
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/34: Tobacco-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed.

## Claims

### Claim at position 1

1: A method of treating pain in a human patient, comprising administering a drug for the treatment of neuropathic and/or neurogenic pain which is an opioid analgesic in a therapeutically effective amount to treat the disease state or condition, to the back of the neck at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy to the human patient.

### Claim at position 2 (depends on 1)

2: The method of claim 1, wherein the drug is selected from the group consisting of morphine, codeine, dihydrocodeine, hydrocodone, hydromorphone, nicomorphine, oxycodone, oxymorphone, fentanyl, alphamethylfentanyl, alfentanil, sufentanil, remifentanil, carfentanyl, ohmefentanyl, thebaine, oripavine, diacetylmorphine (heroin), phenylpiperidines such as pethidine (meperidine) and ketobemidone, allylprodine, prodine, propoxyphene, dextropropoxyphene, dextromoramide, bezitramide, piritramide, methadone, dipipanone, levomethadyl Acetate (LAAM), loperamide, diphenoxylate, dezocine, pentazocine, phenazocine, buprenorphine, dihydroetorphine, etorphine, butorphanol, nalbuphine, levorphanol, levomethorphan, lefetamine, meptazinol, tilidine, tramadol, tapentadol, and mixtures thereof.

### Claim 3

(canceled)

### Claim at position 4 (depends on 2)

4: The method of claim 2, wherein the drug is selected from the group consisting of morphine, codeine, dihydrocodeine, hydrocodone, hydromorphone, oxycodone, oxymorphone, fentanyl, sufentanil, tramadol, and mixtures thereof.

### Claim at position 5 (depends on 2)

5: The method of claim 2, wherein the drug comprises morphine.

### Claim at position 6

6-11. (canceled)

### Claim at position 7 (depends on 1)

12: The method of claim 1, wherein the drug is used in the treatment of neuropathic and/or neurogenic pain.

### Claim at position 8

13-24. (canceled)

### Claim at position 9 (depends on 1)

25: The method of claim 1, wherein the drug is formulated in a pharmaceutically acceptable immediate release topical carrier.

### Claim at position 10 (depends on 25)

26: The method of claim 25, wherein the carrier is aqueous-based.

### Claim at position 11 (depends on 1)

27: The method of claim 1, further comprising formulating the drug in a pharmaceutically acceptable immediate release aqueous-based carrier, and applying a sufficient amount to the back of the neck at the hairline (“BONATH”) of the human patient such that the onset of clinical effect occurs in less than about 30 minutes.

### Claim 28

(canceled)

### Claim at position 13 (depends on 25, 27)

29: The method of claim 27, 25, wherein the carrier is a gel or cream.

### Claim at position 14 (depends on 29)

30: The method of claim 29, further comprising adding at least one adjuvant selected from the group consisting of a penetration enhancer, antioxidant, stabilizer, and mixtures thereof to the carrier.

### Claim at position 15 (depends on 1)

31: The method of claim 1, wherein the drug is incorporated into a sustained release transdermal delivery system which is capable of delivering the drug through the skin of a human patient over a 24 hour period, the transdermal delivery system being capable of delivering the drug in such amounts for a time period from about 1 to about 7 days.

### Claim at position 16 (depends on 31)

32: The method of claim 31, wherein the transdermal delivery system is selected from the group consisting of a transdermal patch, a transdermal plaster, a transdermal disc, and an iontophoretic transdermal device.

### Claim at position 17

33-34. (canceled)

### Claim at position 18 (depends on 1)

35: The method of claim 1, wherein the drug is administered via injection in an immediate release pharmaceutically acceptable carrier for injection.

### Claim at position 19 (depends on 1)

36: The method of claim 1, wherein the drug is administered via injection or implantation in a controlled release carrier to provide a prolonged effect of the drug.

### Claim at position 20 (depends on 1)

37: The method of claim 1, wherein the drug is incorporated into a delivery system selected from the group consisting of a gel, a matrix, microparticles, a pellet, an insert, a colloidal material, and mixtures of any of the foregoing.

### Claim at position 21

38-51. (canceled)

### Claim at position 22

52: A method for treating neuropathic and/or neurogenic pain in a human patient, comprising topically administering an opioid analgesic in an immediate release topical formulation at the back of the neck to provide treatment of neuropathic and/or neurogenic pain in the human patient in less than about 30 minutes after said topical administration.

### Claim at position 23 (depends on 52)

53: The method of claim 52, wherein the drug is selected from the group consisting of morphine, codeine, dihydrocodeine, hydrocodone, hydromorphone, oxycodone, oxymorphone, fentanyl, sufentanil, tramadol, and mixtures thereof.

### Claim at position 24 (depends on 52)

54: The method of claim 52, wherein the drug comprises morphine.

### Claim at position 25 (depends on 52)

55: The method of claim 52, wherein the drug comprises tramadol.

### Claim at position 26 (depends on 52)

56: The method of claim 52, wherein the topical formulation is applied in the form of a cream or gel.
